Antibody neutralization and escape by HIV-1
Top Cited Papers
- 20 March 2003
- journal article
- Published by Springer Nature in Nature
- Vol. 422 (6929) , 307-312
- https://doi.org/10.1038/nature01470
Abstract
Neutralizing antibodies (Nab) are a principal component of an effective human immune response to many pathogens, yet their role in HIV-1 infection is unclear. To gain a better understanding of this role, we examined plasma from patients with acute HIV infection. Here we report the detection of autologous Nab as early as 52 days after detection of HIV-specific antibodies. The viral inhibitory activity of Nab resulted in complete replacement of neutralization-sensitive virus by successive populations of resistant virus. Escape virus contained mutations in the env gene that were unexpectedly sparse, did not map generally to known neutralization epitopes, and involved primarily changes in N-linked glycosylation. This pattern of escape, and the exceptional density of HIV-1 envelope glycosylation generally, led us to postulate an evolving 'glycan shield' mechanism of neutralization escape whereby selected changes in glycan packing prevent Nab binding but not receptor binding. Direct support for this model was obtained by mutational substitution showing that Nab-selected alterations in glycosylation conferred escape from both autologous antibody and epitope-specific monoclonal antibodies. The evolving glycan shield thus represents a new mechanism contributing to HIV-1 persistence in the face of an evolving antibody repertoire.Keywords
This publication has 27 references indexed in Scilit:
- HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sitesNature, 2002
- Human Monoclonal Antibodies Specific for Conformation-Sensitive Epitopes of V3 Neutralize Human Immunodeficiency Virus Type 1 Primary Isolates from Various CladesJournal of Virology, 2002
- Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) MonotherapyAntimicrobial Agents and Chemotherapy, 2002
- Neutralizing Antibodies Associated with Viremia Control in a Subset of Individuals after Treatment of Acute Human Immunodeficiency Virus Type 1 InfectionJournal of Virology, 2001
- GP120: Biologic Aspects of Structural FeaturesAnnual Review of Immunology, 2001
- Increased Neutralization Sensitivity of CD4-Independent Human Immunodeficiency Virus VariantsJournal of Virology, 2001
- The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and ImmunogensScience, 1998
- Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 in Primary Infection and Long‐Term‐Nonprogressive InfectionThe Journal of Infectious Diseases, 1997
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995
- Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous seraAIDS, 1990